Materiały źródłowe

• #1 Atypical Hyperplasia as a Predictor of Future Breast Cancer: Focus on Chemoprevention and Screening – The ASCO Post

  https://ascopost.com/issues/february-25-2015/atypical-hyperplasia-as-a-predictor-of-future-breast-cancer-focus-on-chemoprevention-and-screening.aspx

  Atypical hyperplasia of the breast has special importance as a predictor of future breast cancer, according to a special report in The New England Journal of Medicine. That special importance is based on the high incidence of atypical hyperplasia found in around 10% of the 1 million breast biopsies with benign results performed annually in the United States and the high risk with a cumulative incidence of breast cancer approaching 30% at 25 years of follow-up. […] Because of the incidence, high risk, and availability of effective breast cancer prevention strategies, atypical hyperplasia is the benign breast diagnosis that is the most important to act on clinically, the authors averred. The suggested clinical actions are more intensive screening using magnetic resonance imaging (MRI) and chemoprevention using selective estrogen-receptor modulators and aromatase inhibitors.

• #2 Atypical hyperplasia of the breast: Clinical cases and management strategies | Cleveland Clinic Journal of Medicine

  https://www.ccjm.org/content/90/7/423

  Atypical hyperplasia of the breast is a histopathologic lesion identified incidentally on image-guided breast biopsy. It is associated with a substantial increase in lifetime risk for breast cancer. Clinicians should counsel women with atypical hyperplasia regarding risk-reducing strategies, which include preventive endocrine therapy options, enhanced surveillance imaging, and lifestyle modifications. […] For women with atypical hyperplasia, the cumulative breast cancer risk is approximately 1% per year. […] The US Preventive Services Task Force recommends discussing risk-reducing recommendations with patients who have estimated BCRAT 5-year risk greater than 3%, and the National Comprehensive Cancer Network recommends discussing therapies such as annual mammograms and clinical breast examinations every 6 to 12 months for women age 35 or older and with 5-year risk 1.7% or greater.

• #3 Atypical hyperplasia of the breast: Clinical cases and management strategies | Cleveland Clinic Journal of Medicine

  https://www.ccjm.org/content/90/7/423

  The National Comprehensive Cancer Network guidelines for high-risk women include breast awareness, clinical breast examination every 6 to 12 months, annual screening mammography with possible tomosynthesis, and possible annual breast MRI beginning at diagnosis of ALH. […] Current American Cancer Society guidelines recommend achieving and maintaining a healthy weight and limiting alcohol intake and avoiding smoking to reduce cancer risk. Individually tailored whole foods, plant-based dietary patterns, and 150 to 300 minutes of moderate intensity or 75 to 150 minutes of vigorous intensity activity each week also reduce breast cancer risk. […] Women should be made aware of the considerable decrease in breast cancer risk with healthy lifestyle choices.

• #4 Atypical Hyperplasia of the Breast: Follow-up and Management – The ObG Project

  https://www.obgproject.com/2017/04/19/atypical-hyperplasia-breast-follow-management/

  Atypical hyperplasia of the breast is a benign but high-risk condition that can be either ductal (ADH) or lobular (ALH); these occur with equal frequency and together are found in about 10% of breast biopsies. […] Follow-up screening recommendations include annual mammography, breast awareness, and clinical encounter every 6 to 12 months. […] Encourage pharmacologic risk reduction with either a selective estrogen-receptor modulator (SERM) or an aromatase inhibitor (AI) for prevention of breast cancer. […] Counsel about healthy lifestyle including ideal body weight and alcohol reduction. […] Atypical hyperplasia is generally not an indication for surgical risk-reduction / mastectomy.

• #5 Atypical Hyperplasia – Tower Love Fund – Breast Cancer Explained

  https://www.towercancer.org/resource/breast-cancer-explained/atypical-hyperplasia/

  Atypical ductal hyperplasia (ADH) increases your risk of breast cancer occurring in the breast where the ADH was found. Atypical lobular hyperplasia (ALH) increases your risk of developing breast cancer in both breasts. Keep in mind, though, the vast majority of women diagnosed with ADH or ALH never go on to develop breast cancer. […] The standard treatment for atypical hyperplasia is close follow-up. Monitoring is especially important if you have a strong family history of breast cancer. If you do, you may want to ask your doctor to recommend a program for high-risk women. These programs provide close follow-up, which means clinical breast exams every six months and yearly mammograms. […] If you are diagnosed with atypical hyperplasia, your doctor may suggest that you consider taking tamoxifen. If you are postmenopausal, raloxifene (Evista) may be an option for you as well. Both drugs come in pill form and are taken daily for five years.

• #6 Breast Hyperplasia (Ductal or Lobular) | Benign Conditions | American Cancer Society

  https://www.cancer.org/cancer/types/breast-cancer/non-cancerous-breast-conditions/hyperplasia-of-the-breast-ductal-or-lobular.html

  Hyperplasia can affect your risk for breast cancer, but how much depends on what type it is: […] Atypical hyperplasia (either ADH or ALH): The risk of breast cancer is about 4 to 5 times higher than that of a woman with no breast abnormalities. More details about pathology reports showing atypical hyperplasia can be found in Understanding Your Pathology Report: Atypical Hyperplasia. […] Both ADH and ALH are linked to a higher risk of breast cancer. Even though most women with ADH or ALH will not develop breast cancer, it’s still important to talk with a health care provider about your risk and what you can do about it. […] Options for women at higher risk of breast cancer from ADH or ALH may include: Seeing a health care provider more often (such as every 6 to 12 months) for a breast exam along with a yearly mammogram. Additional imaging with breast MRIs may also be recommended, especially if you have other factors that raise your risk of breast cancer. […] Making lifestyle changes to lower breast cancer risk. […] Taking medicine to help lower breast cancer risk.

• #7 Contemporary management of atypical breast lesions identified on percutaneous biopsy: a narrative review – Amin – Annals of Breast Surgery

  https://abs.amegroups.org/article/view/6578/html

  The management of atypical breast lesions identified on core needle biopsy (CNB) for a breast imaging abnormality is a topic of controversy. […] With the exception of FEA, regardless of whether the site of atypia is excised or not, the patient is also at increased risk of future breast cancer in both breasts. The highest lifetime risk is in women with LCIS. Lifestyle modification, high-risk screening, discussion of chemoprevention, and even bilateral risk-reducing mastectomy may be appropriate for those at a lifetime risk 50%. […] NCCN management recommendations for patients diagnosed with atypia include clinical encounter every six to twelve months, annual MMG after age 30, consider annual MRI after age 25, risk reduction strategies, and breast awareness. […] American Society of Clinical Oncology (ASCO) guidelines recommend chemoprevention be discussed with women with a 5-year absolute risk of breast cancer of 1.7% or higher. Chemoprevention with tamoxifen, raloxifene, anastrozole, or exemestane results in a 50% reduction in future malignancy risk. This risk reduction is even more significant in women with LN and ADH ranging from 6570%, when compared to those with a family history of breast cancer without an atypia diagnosis. […] Recognition that future breast cancer risk persists even after atypia excision is vital, and appropriate counseling about lifestyle modification, increased intensity of breast screening, and discussion of chemoprevention should be offered.

• #8 Atypical hyperplasia of the breast: Clinical cases and management strategies | Cleveland Clinic Journal of Medicine

  https://www.ccjm.org/content/90/7/423

  The National Comprehensive Cancer Network guidelines for high-risk women include breast awareness, clinical breast examination every 6 to 12 months, annual screening mammography with possible tomosynthesis, and possible annual breast MRI beginning at diagnosis of ALH. […] Current American Cancer Society guidelines recommend achieving and maintaining a healthy weight and limiting alcohol intake and avoiding smoking to reduce cancer risk. Individually tailored whole foods, plant-based dietary patterns, and 150 to 300 minutes of moderate intensity or 75 to 150 minutes of vigorous intensity activity each week also reduce breast cancer risk. […] Women should be made aware of the considerable decrease in breast cancer risk with healthy lifestyle choices.

• #9 Azthena logo with the word Azthena

  https://www.news-medical.net/health/Atypical-Hyperplasia-and-Breast-Cancer-Risk.aspx

  Atypical hyperplasia is described as an accumulation of abnormal cells in the breast. It is not cancer, but can be a pre-cancerous condition. […] Women diagnosed with atypical hyperplasia are at 4 times higher risk of breast cancer than women without it. […] It is important to discuss your risk of developing breast cancer with your physician. Understanding ones cancer risk clearly aids in making critical decisions about cancer screening and risk-reducing medications. […] Special breast cancer screening recommendations are in place for women diagnosed with atypical hyperplasia. These are intended to help in catching the development of breast cancer, if any, at an early stage, when it can be treated easily and successfully. […] According to National Comprehensive Cancer Network (NCCN) recommendations, women with atypical hyperplasia should have a clinical breast examination every 6 to 12 months after 30 years of age, and have a mammogram once a year starting at age 30 years. […] Women having atypical hyperplasia can be treated with drugs that reduce their risk of developing breast cancer. Tamoxifen and raloxifene are the 2 main FDA-approved drugs used in such cases, both of which are taken in pill form.

• #10 Impact of preventive therapy on the risk of breast cancer among women with benign breast disease

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4636510/

  There are three main ways in which women can be identified as being at high risk of breast cancer i) family history of breast and/or ovarian cancer, which includes genetic factors ii) mammographically identified high breast density, and iii) certain types of benign breast disease. […] More common is atypical hyperplasia (AH), which carries a 45-fold risk of breast cancer as compared to general population. […] Tamoxifen has been shown to be particularly effective in preventing subsequent breast cancer in women with AH, with a more than 70% reduction in the P1 trial and a 60% reduction in IBIS-I. […] Improving diagnostic consistency, breast cancer risk prediction and education of physicians and patients regarding therapeutic prevention in women with benign breast disease may strengthen breast cancer prevention efforts.

• #11 The role of chemoprevention in modifying the risk of breast cancer in women with atypical breast lesions – PubMed

  https://pubmed.ncbi.nlm.nih.gov/23117858/

  Women with atypical ductal hyperplasia (ADH), atypical lobular hyperplasia (ALH), lobular carcinoma in situ (LCIS), and severe ADH are at increased risk of breast cancer, but a systematic quantification of this risk and the efficacy of chemoprevention in the clinical setting is still lacking. […] Chemoprevention use significantly reduced breast cancer risk for all atypia types (p 0.05). The risk of breast cancer with atypical breast lesions is substantial. Physicians should counsel patients with ADH, ALH, LCIS, and severe ADH about the benefit of chemoprevention in decreasing their breast cancer risk.

• #12 Atypical Hyperplasia Treatment | New England Breast And Wellness

  https://www.nebreastandwellness.com/treatments/atypical-hyperplasia-treatment/

  Atypical hyperplasia is a precancerous condition related to the cells in the breast. […] After diagnosing atypical hyperplasia, your doctor may recommend atypical hyperplasia treatment to reduce the risk of breast cancer. […] The follow-up program includes clinical breast exams once every six months and annual mammograms. Your doctor may also recommend various medications for breast cancer prevention (chemoprevention), such as tamoxifen and raloxifene. […] A clinical study conducted in the 90s found that tamoxifen reduced the risk of breast cancer amongst women with atypia (abnormal cells in the milk ducts or lobules) by 86% this study paved the way for tamoxifen being used for chemoprevention. […] Raloxifene is an oral medication taken daily for five years, meant specifically for post-menopausal women with a high risk of breast cancer. This drug was approved for breast cancer risk reduction after a STAR (Study of Tamoxifen and Raloxifene) trial determined that it offered similar benefits as tamoxifen.

• #13 Contemporary management of atypical breast lesions identified on percutaneous biopsy: a narrative review – Amin – Annals of Breast Surgery

  https://abs.amegroups.org/article/view/6578/html

  The management of atypical breast lesions identified on core needle biopsy (CNB) for a breast imaging abnormality is a topic of controversy. […] With the exception of FEA, regardless of whether the site of atypia is excised or not, the patient is also at increased risk of future breast cancer in both breasts. The highest lifetime risk is in women with LCIS. Lifestyle modification, high-risk screening, discussion of chemoprevention, and even bilateral risk-reducing mastectomy may be appropriate for those at a lifetime risk 50%. […] NCCN management recommendations for patients diagnosed with atypia include clinical encounter every six to twelve months, annual MMG after age 30, consider annual MRI after age 25, risk reduction strategies, and breast awareness. […] American Society of Clinical Oncology (ASCO) guidelines recommend chemoprevention be discussed with women with a 5-year absolute risk of breast cancer of 1.7% or higher. Chemoprevention with tamoxifen, raloxifene, anastrozole, or exemestane results in a 50% reduction in future malignancy risk. This risk reduction is even more significant in women with LN and ADH ranging from 6570%, when compared to those with a family history of breast cancer without an atypia diagnosis. […] Recognition that future breast cancer risk persists even after atypia excision is vital, and appropriate counseling about lifestyle modification, increased intensity of breast screening, and discussion of chemoprevention should be offered.

• #14 Atypical Hyperplasia of the Breast — Risk Assessment and Management Options – Breast360.org

  https://breast360.org/news/2015/09/15/atypical-hyperplasia-breast-risk-assessment-and-ma/

  97% of atypical ductal hyperplasia and 88% of atypical lobular hyperplasia has estrogen receptor staining, meaning it is stimulated by estrogen. Because of this, medications called selective estrogen receptor modulators (for example, tamoxifen and raloxifene) and aromatase inhibitors (for example, exemestane, anastrozole, and letrozole) have been shown in clinical trials to effectively reduce the risk of breast cancer associated with these lesions. A recent meta-analysis of selective estrogen receptor modulator trials found a 38% relative reduction in the risk of breast cancer in those taking the medication. Relative risk reductions in the atypical hyperplasia subgroup were even greater and ranged from 41% up to 79%. […] Despite the evidence that chemoprevention medications work, patients are reluctant to take them due to fear of side effects.

• #15 Atypical Hyperplasia of the Breast — Risk Assessment and Management Options – Breast360.org

  https://breast360.org/news/2015/09/15/atypical-hyperplasia-breast-risk-assessment-and-ma/

  97% of atypical ductal hyperplasia and 88% of atypical lobular hyperplasia has estrogen receptor staining, meaning it is stimulated by estrogen. Because of this, medications called selective estrogen receptor modulators (for example, tamoxifen and raloxifene) and aromatase inhibitors (for example, exemestane, anastrozole, and letrozole) have been shown in clinical trials to effectively reduce the risk of breast cancer associated with these lesions. A recent meta-analysis of selective estrogen receptor modulator trials found a 38% relative reduction in the risk of breast cancer in those taking the medication. Relative risk reductions in the atypical hyperplasia subgroup were even greater and ranged from 41% up to 79%. […] Despite the evidence that chemoprevention medications work, patients are reluctant to take them due to fear of side effects.

• #16

  https://www.archbreastcancer.com/index.php/abc/article/view/190

  Women with atypical hyperplasia are about 4 times more likely to develop breast cancer compared with the general population. Atypical hyperplasia has been recommended to be used as a criterion for the inclusion of women in chemoprevention programs. Chemoprevention offers promise as a strategy for reducing the incidence of breast cancer in high-risk population. […] It is believed that the initiation of chemoprevention would be appropriate if the 10-year breast cancer risk is 4% to 8%. Breast cancer risk reduction by chemoprevention is reported to be 32% to 55% in breast atypia. […] According to our findings, patients with a diagnosis of ADH, ALH, or severe ADH should be considered for chemoprevention if they are at least 35 years of age and have no contraindications to treatment. Only 4%20% of high-risk women decide to take chemoprevention, on average.

• #17

  https://www.archbreastcancer.com/index.php/abc/article/view/190

  Women with atypical hyperplasia are about 4 times more likely to develop breast cancer compared with the general population. Atypical hyperplasia has been recommended to be used as a criterion for the inclusion of women in chemoprevention programs. Chemoprevention offers promise as a strategy for reducing the incidence of breast cancer in high-risk population. […] It is believed that the initiation of chemoprevention would be appropriate if the 10-year breast cancer risk is 4% to 8%. Breast cancer risk reduction by chemoprevention is reported to be 32% to 55% in breast atypia. […] According to our findings, patients with a diagnosis of ADH, ALH, or severe ADH should be considered for chemoprevention if they are at least 35 years of age and have no contraindications to treatment. Only 4%20% of high-risk women decide to take chemoprevention, on average.

• #18 Atypical Hyperplasia Treatment | New England Breast And Wellness

  https://www.nebreastandwellness.com/treatments/atypical-hyperplasia-treatment/

  Chemoprevention may increase the risk of numerous side effects, such as pulmonary embolism (blood clots in the lungs), deep vein thrombosis (blood clots in veins), and strokes. While the risk is relatively small, it shouldn’t be ignored. That’s why you should determine if you want to start chemoprevention after weighing the risks and benefits with your doctor.

• #19 Atypical hyperplasia of the breast: Clinical cases and management strategies | Cleveland Clinic Journal of Medicine

  https://www.ccjm.org/content/90/7/423

  The National Comprehensive Cancer Network guidelines for high-risk women include breast awareness, clinical breast examination every 6 to 12 months, annual screening mammography with possible tomosynthesis, and possible annual breast MRI beginning at diagnosis of ALH. […] Current American Cancer Society guidelines recommend achieving and maintaining a healthy weight and limiting alcohol intake and avoiding smoking to reduce cancer risk. Individually tailored whole foods, plant-based dietary patterns, and 150 to 300 minutes of moderate intensity or 75 to 150 minutes of vigorous intensity activity each week also reduce breast cancer risk. […] Women should be made aware of the considerable decrease in breast cancer risk with healthy lifestyle choices.

• #20 Atypical hyperplasia of the breast | UM Health-Sparrow

  https://www.uofmhealthsparrow.org/departments-conditions/conditions/atypical-hyperplasia-breast

  Aim for at least 30 minutes of exercise on most days of the week. If you haven’t been active lately, ask a healthcare professional whether it’s OK and start slowly. […] Hormone therapy treatments used to ease menopause symptoms may increase the risk of breast cancer. Talk with a healthcare professional about the benefits and risks of hormone therapy. […] If your weight is healthy, work to maintain that weight. If you need to lose weight, ask a healthcare professional about healthy ways to lower your weight. Eat fewer calories and slowly increase the amount of exercise. […] Avoid hormone therapy for menopause. Certain kinds of medicines that use hormones to help control symptoms of menopause can increase the risk of breast cancer. If you have menopause symptoms, ask your healthcare team about treatments that won’t increase your risk of breast cancer.

• #21 Atypical Ductal Hyperplasia: Breast, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/16242-atypical-ductal-hyperplasia

  Atypical ductal hyperplasia is a general category that includes two types. […] While you cant prevent ADH, you can take steps to reduce your risk. Some of these steps include: Maintain a healthy weight. Exercise daily. Limit or avoid beverages containing alcohol. Avoid smoking cigarettes and using tobacco products. (If you smoke or use tobacco, your provider can give you resources to help you quit.) […] Follow your healthcare providers instructions for follow-up care. This involves attending all breast cancer screenings and making healthy lifestyle choices to reduce your risk. Lifestyle choices could include maintaining a healthy weight, exercising regularly and avoiding beverages containing alcohol.

• #22 Atypical cells in a breast lump | Other Conditions | Cancer Research UK

  https://www.cancerresearchuk.org/about-cancer/breast-cancer/types/atypical-hyperplasia-breast-lump

  Atypical hyperplasia can increase your risk of developing breast cancer in the future. […] Some factors can help to reduce the risk of breast cancer in general. These include: being physically active, having a healthy diet and limiting the amount of alcohol you have. […] There are some things that can help to reduce the risk of breast cancer, this includes keeping a healthy weight, eating a healthy diet and being physically active. Find out what else you can do.

• #23 Navigating breast health: a comprehensive approach to atypical ductal hyperplasia of the breast management and surveillance

  https://www.explorationpub.com/Journals/em/Article/1001205

  Atypical ductal hyperplasia (ADH) is a benign lesion of the breast that is associated with an increased risk of invasive breast cancer. […] The management plan for patients diagnosed with ADH includes regular clinical surveillance, diagnostic mammography, along with risk-reduction strategies such as lifestyle modifications or the use of adjuvant endocrine therapies. […] According to National Comprehensive Cancer Network (NCCN) recommendations, patients diagnosed with ADH should be offered lifetime surveillance. This includes a clinical breast examination every 6-12 months and an annual digital diagnostic MMO with tomosynthesis beginning at the age of diagnosis of ADH but not prior to the age of 30. […] Risk reduction strategies include lifestyle modifications such as healthy diet, regular aerobic exercise, maintaining ideal body weight, and avoidance of smoking and alcohol consumption.

• #24 Atypical hyperplasia of the breast: Clinical cases and management strategies | Cleveland Clinic Journal of Medicine

  https://www.ccjm.org/content/90/7/423

  The National Comprehensive Cancer Network guidelines for high-risk women include breast awareness, clinical breast examination every 6 to 12 months, annual screening mammography with possible tomosynthesis, and possible annual breast MRI beginning at diagnosis of ALH. […] Current American Cancer Society guidelines recommend achieving and maintaining a healthy weight and limiting alcohol intake and avoiding smoking to reduce cancer risk. Individually tailored whole foods, plant-based dietary patterns, and 150 to 300 minutes of moderate intensity or 75 to 150 minutes of vigorous intensity activity each week also reduce breast cancer risk. […] Women should be made aware of the considerable decrease in breast cancer risk with healthy lifestyle choices.

• #25 Atypical hyperplasia of the breast – Symptoms and causes – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/atypical-hyperplasia/symptoms-causes/syc-20369773

  Hormone therapy treatments used to ease menopause symptoms may increase the risk of breast cancer. Talk with a healthcare professional about the benefits and risks of hormone therapy. […] If your weight is healthy, work to maintain that weight. If you need to lose weight, ask a healthcare professional about healthy ways to lower your weight. Eat fewer calories and slowly increase the amount of exercise.

• #26 Atypical hyperplasia of the breast | UM Health-Sparrow

  https://www.uofmhealthsparrow.org/departments-conditions/conditions/atypical-hyperplasia-breast

  Aim for at least 30 minutes of exercise on most days of the week. If you haven’t been active lately, ask a healthcare professional whether it’s OK and start slowly. […] Hormone therapy treatments used to ease menopause symptoms may increase the risk of breast cancer. Talk with a healthcare professional about the benefits and risks of hormone therapy. […] If your weight is healthy, work to maintain that weight. If you need to lose weight, ask a healthcare professional about healthy ways to lower your weight. Eat fewer calories and slowly increase the amount of exercise. […] Avoid hormone therapy for menopause. Certain kinds of medicines that use hormones to help control symptoms of menopause can increase the risk of breast cancer. If you have menopause symptoms, ask your healthcare team about treatments that won’t increase your risk of breast cancer.

• #27 Atypical hyperplasia of the breast – Augusta HealthSearchClose SearchSearch IconSearch IconClose Search IconMobile Menu IconMobile Menu Close IconInstagramFacebookTwitterYoutube

  https://www.augustahealth.com/disease/atypical-hyperplasia-of-the-breast/

  Take preventive medications. Treatment with a selective estrogen receptor modulator, such as tamoxifen or raloxifene (Evista), for five years may reduce the risk of breast cancer. […] Avoid menopausal hormone therapy. Researchers have concluded that combination hormone therapy to treat symptoms of menopause — estrogen plus progestin — increases breast cancer risk after menopause. […] Consider risk-reducing (prophylactic) mastectomy. If you have a very high risk of breast cancer, a risk-reducing mastectomy — surgery to remove one or both breasts — may be an option to reduce the risk of developing breast cancer in the future. […] Make healthy lifestyle choices. Make healthy choices in your daily life in order to reduce your risk of breast cancer. For instance, exercise most days of the week, maintain a healthy weight, don’t smoke and limit the amount of alcohol you drink, if you choose to drink alcohol.

• #28 “ATYPICAL HYPERPLASIA OF THE BREAST: CANCER RISK-REDUCTION STRATEGIES” | MDedge

  https://www.mdedge.com/obgmanagement/article/102525/atypical-hyperplasia-breast-cancer-risk-reduction-strategies

  Is the risk of EPT substantially higher? […] I agree that women who have atypical hyperplasia should be counseled to consider the possible additional risk of hormone use. […] Accordingly, since women with a prior biopsy diagnosis of AH have a 4-fold elevated risk of being diagnosed with invasive breast cancer, it is reasonable to speculate that EPT would elevate this risk to some 4 additional cases per 1,000 person-years of use. This is why we recommend that women with a history of AH considering use of EPT be counseled regarding this potential elevated risk of being diagnosed with invasive breast cancer.

• #29 Menopausal symptom management considerations in patients at high risk for breast cancer – Women’s Healthcare

  https://www.npwomenshealthcare.com/menopausal-symptom-management-considerations-in-patients-at-high-risk-for-breast-cancer/

  Risk-reducing medications, also referred to as endocrine therapy (previously known as chemoprevention), are extremely effective in reducing breast cancer risk, especially for those with atypical hyperplasia and LCIS. […] Having atypical hyperplasia or LCIS are strong indications to begin a risk-reducing agent, so patients with a history of biopsy results revealing those findings may also want to consider alternatives to hormone therapy for the management of menopausal symptoms. […] Prior to starting endocrine therapy, numerous additional factors need to be taken into consideration, including a determination of pre- versus postmenopausal status, contraindications to use, risks and side effects of the medication, and overall estimated risk-reduction benefit. […] For patients taking risk-reducing medications, guidelines such as the NCCN recommend against the use of HT for menopausal symptom management. […] Understanding which breast cancer risk factors warrant intervention and the types of intervention recommended can help the clinician navigate the decision tree of balancing breast cancer risk with menopause symptom management in a shared decision-making framework with their patients.

• #30 Atypical hyperplasia of the breast – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/atypical-hyperplasia/diagnosis-treatment/drc-20369778

  Atypical hyperplasia of the breast increases the risk of breast cancer. So your healthcare team creates a breast cancer screening plan. You might have more-frequent screening or different screening tests than would someone with an average risk of breast cancer. […] To reduce your risk of breast cancer, your healthcare team may recommend that you: […] Consider surgery to lower the risk of breast cancer. If you have a very high risk of breast cancer, your healthcare team might recommend surgery to lower your risk. Your risk might be high if you have a strong family history of breast cancer. Your risk also may be high if DNA changes that increase the risk of breast cancer run in your family. One operation that can lower the risk of breast cancer is surgery to remove both breasts. This procedure is called a risk-reducing mastectomy or a prophylactic mastectomy.

• #31 Atypical Hyperplasia | Memorial Sloan Kettering Cancer Center

  https://www.mskcc.org/cancer-care/patient-education/atypical-hyperplasia

  This information will help you understand atypical hyperplasia and how it can affect your risk of getting breast cancer. It also explains what you can do to prevent breast cancer. […] Because of the increased breast cancer risk, people with either type of atypical hyperplasia should get regular breast exams and breast imaging tests. […] Taking certain medications can help lower your risk of getting breast cancer. […] Some people may choose to have their breasts removed to prevent breast cancer. This is called a bilateral prophylactic (PRO-fih-LAK-tik) mastectomy. This surgery is sometimes used to lower the risk of breast cancer in people with ADH or ALH. […] There are also lifestyle changes you can make to lower your breast cancer risk if you have LCIS. You can talk with your healthcare provider about these lifestyle changes.

• #32 Atypical Hyperplasia – Tower Love Fund – Breast Cancer Explained

  https://www.towercancer.org/resource/breast-cancer-explained/atypical-hyperplasia/

  Chemoprevention with tamoxifen or raloxifene is not a mandatory treatment. It is a choice. To decide whether it is right for you, you need to weigh the risks versus the benefits. […] If you have a family history of breast cancer in addition to ADH or ALH and you want to understand more about whether your family history may contribute to your breast cancer risk, you should make an appointment with a genetic counselor to discuss testing for the hereditary breast cancer gene mutations, called BRCA1 and BRCA2, which put women at higher risk for breast and ovarian cancer. […] If you decide to have genetic testing and if you are found to carry one of the BRCA gene mutations that put women at higher risk for breast and ovarian cancer, your doctor may suggest that you consider a bilateral prophylactic mastectomy (removal of both breasts). This will reduce the chance of getting breast cancer by about 95%. The surgery is only recommended if you have a strong family history of the disease. It is not recommended for women just because they have had a diagnosis of atypical hyperplasia.

• #33 Atypical Hyperplasia as a Predictor of Future Breast Cancer: Focus on Chemoprevention and Screening – The ASCO Post

  https://ascopost.com/issues/february-25-2015/atypical-hyperplasia-as-a-predictor-of-future-breast-cancer-focus-on-chemoprevention-and-screening.aspx

  Atypical hyperplasia is generally not an indication for prophylactic mastectomy, according to the report. Ultimately, it is really a matter of a woman’s choice, Dr. Degnim stressed. However, we would favor other approaches, such as prevention medications and MRI screening rather than mastectomy. […] Several statements in the special report support the use of selective estrogen-receptor modulators and aromatase inhibitors to prevent breast cancer in women with atypical hyperplasia. […] We hope that having more accurate assessment of an individual woman’s risk will help patients to benefit from prevention medications, Dr. Degnim said. Knowing that their risk approaches 30% at 25 years may motivate them more strongly to stay on their risk-reduction medication.

• #34 Prophylactic Bilateral Mastectomy (BPM) on Moderate Risk Patients with Atypical Ductal Hyperplasia | Nashua Personal Injury Lawyers Blog | September 18, 2023

  https://www.granite-law-group.com/blog/prophylactic-bilateral-mastectomy/

  When a woman undergoes a core biopsy and is diagnosed with Atypical Ductal Hyperplasia (ADH), the news is undoubtedly scary. Afterall, ADH is a finding of pre-cancerous cell growth which is associated with long term increased risk of breast cancer. […] Some female patients respond by electing to undergo a Bilateral Prophylactic Mastectomy (BPM). […] The acceptable risk of developing breast cancer is a relative term that varies with the individual patient. […] Before the patient elects to undergo a BPM, the Society of Surgical Oncology adds the caveat that it is best practice for the patient to first be evaluated by a multidisciplinary team of providers. […] This will allow the patient to make an informed decision about whether nonsurgical interventions are a better fit for their circumstances versus radical BPM.

• #35 Atypical Hyperplasia as a Predictor of Future Breast Cancer: Focus on Chemoprevention and Screening – The ASCO Post

  https://ascopost.com/issues/february-25-2015/atypical-hyperplasia-as-a-predictor-of-future-breast-cancer-focus-on-chemoprevention-and-screening.aspx

  Atypical hyperplasia is generally not an indication for prophylactic mastectomy, according to the report. Ultimately, it is really a matter of a woman’s choice, Dr. Degnim stressed. However, we would favor other approaches, such as prevention medications and MRI screening rather than mastectomy. […] Several statements in the special report support the use of selective estrogen-receptor modulators and aromatase inhibitors to prevent breast cancer in women with atypical hyperplasia. […] We hope that having more accurate assessment of an individual woman’s risk will help patients to benefit from prevention medications, Dr. Degnim said. Knowing that their risk approaches 30% at 25 years may motivate them more strongly to stay on their risk-reduction medication.

• #36 Atypical Hyperplasia – Tower Love Fund – Breast Cancer Explained

  https://www.towercancer.org/resource/breast-cancer-explained/atypical-hyperplasia/

  Chemoprevention with tamoxifen or raloxifene is not a mandatory treatment. It is a choice. To decide whether it is right for you, you need to weigh the risks versus the benefits. […] If you have a family history of breast cancer in addition to ADH or ALH and you want to understand more about whether your family history may contribute to your breast cancer risk, you should make an appointment with a genetic counselor to discuss testing for the hereditary breast cancer gene mutations, called BRCA1 and BRCA2, which put women at higher risk for breast and ovarian cancer. […] If you decide to have genetic testing and if you are found to carry one of the BRCA gene mutations that put women at higher risk for breast and ovarian cancer, your doctor may suggest that you consider a bilateral prophylactic mastectomy (removal of both breasts). This will reduce the chance of getting breast cancer by about 95%. The surgery is only recommended if you have a strong family history of the disease. It is not recommended for women just because they have had a diagnosis of atypical hyperplasia.

• #37 How to reduce your breast cancer risk | MD Anderson Cancer Center

  https://www.mdanderson.org/cancerwise/how-to-reduce-your-breast-cancer-risk.h00-159696756.html

  Certain non-cancerous breast tissue conditions can increase the risk for breast cancer. These include hyperplasia, atypical hyperplasia and lobular carcinoma in situ. These are usually found during a mammogram and diagnosed after a biopsy. […] It is important to let your doctor know if breast cancer runs in your family. […] If you are at a higher risk for breast cancer, you may need to start screening earlier than what is listed on screening guidelines. […] A healthy lifestyle, a balanced diet and getting your cancer screening exams are all important steps to reduce your risk of cancer.

• #38 Atypical hyperplasia of the breast – Diagnosis and treatment – Mayo Clinic

  https://www.mayoclinic.org/diseases-conditions/atypical-hyperplasia/diagnosis-treatment/drc-20369778

  Make healthy lifestyle choices. Make healthy choices in your daily life to reduce your risk of breast cancer. For instance, exercise most days of the week and maintain a healthy weight. Don’t smoke. Limit the amount of alcohol you drink, if you choose to drink alcohol. For breast cancer prevention, there is no safe amount of alcohol. So if you’re very concerned about your breast cancer risk, you may choose to not drink alcohol. […] Participate in a clinical trial. Clinical trials test new treatments. Trials testing the best way to manage the risk of breast cancer in people with atypical hyperplasia may be available. Ask your healthcare team about clinical trials.

• #39 Atypical hyperplasia of the breast // Middlesex Health

  https://middlesexhealth.org/learning-center/diseases-and-conditions/atypical-hyperplasia-of-the-breast

  Limit the amount of alcohol you drink to no more than one drink a day, if you choose to drink. […] Aim for at least 30 minutes of exercise on most days of the week. […] Talk with a healthcare professional about the benefits and risks of hormone therapy. […] If your weight is healthy, work to maintain that weight. If you need to lose weight, ask a healthcare professional about healthy ways to lower your weight. […] If you have a very high risk of breast cancer, your healthcare team might recommend surgery to lower your risk. […] Make healthy choices in your daily life to reduce your risk of breast cancer. […] Clinical trials test new treatments. Trials testing the best way to manage the risk of breast cancer in people with atypical hyperplasia may be available.

• #40 Metformin Hydrochloride in Preventing Breast Cancer in Patients With Atypical Hyperplasia or In Situ Breast Cancer | Division of Cancer Prevention

  https://prevention.cancer.gov/clinical-trials/clinical-trials-search/nct01905046

  This randomized phase III trial studies metformin hydrochloride to see how well it works compared to placebo in preventing breast cancer in patients with atypical hyperplasia or in situ breast cancer. […] The use of metformin hydrochloride may prevent breast cancer.

• #41 Atypical hyperplasia of the breast

  https://www.mymlc.com/health-information/diseases-and-conditions/a/atypical-hyperplasia-of-the-breast2/?section=Causes

  If you’ve been diagnosed with atypical hyperplasia, you have an increased risk of developing breast cancer in the future. […] For this reason, doctors often recommend intensive breast cancer screening and medications to reduce breast cancer risk. […] To reduce your risk of developing breast cancer, your doctor may recommend that you: […] Take preventive medications. Treatment with a selective estrogen receptor modulator, such as tamoxifen or raloxifene (Evista), for five years may reduce the risk of breast cancer. […] Avoid menopausal hormone therapy. Researchers have concluded that combination hormone therapy to treat symptoms of menopause — estrogen plus progestin — increases breast cancer risk after menopause. […] Participate in a clinical trial. Clinical trials test new treatments not yet available to the public at large that may prove helpful in reducing breast cancer risk associated with atypical hyperplasia.

• #42 Atypical hyperplasia of the breast: Clinical cases and management strategies | Cleveland Clinic Journal of Medicine

  https://www.ccjm.org/content/90/7/423

  The American Cancer Society recommends magnetic resonance imaging (MRI) breast screening for patients with a calculated lifetime breast cancer risk of at least 20% based on IBIS. […] Because studies show that the lifetime risk of breast cancer is greater than 20% for women with atypical hyperplasia, the role of annual MRI plus mammography surveillance is appropriate. […] Risk-reducing endocrine therapy should be discussed with patients because of increased lifetime risk of breast cancer, estimated at 1% per year. […] Risk-reducing endocrine therapy for the prevention of breast cancer is associated with a 41% to 79% relative risk reduction for women with ALH. […] The approach to discussing risk-reducing endocrine therapy for women with atypical hyperplasia should be individualized according to menopausal status, medical comorbidities, and risk of adverse effects.

• #43

  https://www.healio.com/news/hematology-oncology/20160915/breast-cancer-risk-after-atypical-ductal-hyperplasia-may-be-overstated

  Atypical ductal hyperplasia is a known risk factor for breast cancer, and previous reports estimate the risk for invasive breast cancer after an atypical ductal hyperplasia diagnosis is 29% over 25 years. […] Women with atypical ductal hyperplasia diagnosed by core needle and excisional biopsy had a slightly lower risk [for] invasive breast cancer than noted in previously reported studies, Menes and colleagues wrote. Because the risk associated with atypical ductal hyperplasia is modified in the presence of other risk factors, clinicians should not recommend increased surveillance and risk-reducing strategies without accounting for other factors. An assessment of an individuals risk based on multiple factors should be preferred before deciding on prevention strategies. […] Chemoprevention should be discussed with patients, especially in high-risk groups, such as white women and those with a family history of breast cancer, dense breast tissues, or a history of breast biopsies.

• #44 Atypical Hyperplasia of the Breast — Risk Assessment and Management Options – Breast360.org

  https://breast360.org/news/2015/09/15/atypical-hyperplasia-breast-risk-assessment-and-ma/

  The younger a woman is when she receives a diagnosis of atypical ductal hyperplasia, the more likely it is that breast cancer will develop in her lifetime; however, if women with atypical ductal hyperplasia take medication to prevent breast cancer, their risk of developing breast cancer may be reduced by over 40% and up to approximately 80%. […] Clinical trials have shown pharmacologic risk reduction (taking medication to prevent cancer) to be effective in women with atypical hyperplasia Tamoxifen, raloxifene (Evista) and exemestane have been proven to reduce the risk of developing breast cancer in women who have atypical hyperplasia. […] Education regarding chemoprevention (taking medication to prevent cancer) should describe a woman’s absolute risk of breast cancer, the anticipated reduction in risk, and the absolute risks of various side effects. An individual’s personal benefits and risks of taking risk-reduction medication should be discussed with her physician.

• #45 Risks, Management of Atypical Hyperplasia of Breast Discussed – MPR

  https://www.empr.com/home/news/drug-news/risks-management-of-atypical-hyperplasia-of-breast-discussed/

  Atypical hyperplasia is associated with increased breast cancer risk, and consequently, women should be educated regarding their risk of developing breast cancer and the potential risk reduction associated with chemoprevention, according to a special report published in the January 1 issue of the New England Journal of Medicine. […] For women with atypical hyperplasia, randomized controlled trials have shown the effectiveness of pharmacologic risk reduction, but few women use chemopreventive agents. Education relating to chemoprevention should include the absolute risk of breast cancer, anticipated risk reduction, and risks of side effects. […] Additional research is needed to advance the understanding and management of atypical hyperplasia, the authors write.

• #46 Impact of preventive therapy on the risk of breast cancer among women with benign breast disease

  https://pmc.ncbi.nlm.nih.gov/articles/PMC4636510/

  There are three main ways in which women can be identified as being at high risk of breast cancer i) family history of breast and/or ovarian cancer, which includes genetic factors ii) mammographically identified high breast density, and iii) certain types of benign breast disease. […] More common is atypical hyperplasia (AH), which carries a 45-fold risk of breast cancer as compared to general population. […] Tamoxifen has been shown to be particularly effective in preventing subsequent breast cancer in women with AH, with a more than 70% reduction in the P1 trial and a 60% reduction in IBIS-I. […] Improving diagnostic consistency, breast cancer risk prediction and education of physicians and patients regarding therapeutic prevention in women with benign breast disease may strengthen breast cancer prevention efforts.

• #47 Atypical Ductal Hyperplasia: Breast, Symptoms & Treatment

  https://my.clevelandclinic.org/health/diseases/16242-atypical-ductal-hyperplasia

  Atypical ductal hyperplasia is a general category that includes two types. […] While you cant prevent ADH, you can take steps to reduce your risk. Some of these steps include: Maintain a healthy weight. Exercise daily. Limit or avoid beverages containing alcohol. Avoid smoking cigarettes and using tobacco products. (If you smoke or use tobacco, your provider can give you resources to help you quit.) […] Follow your healthcare providers instructions for follow-up care. This involves attending all breast cancer screenings and making healthy lifestyle choices to reduce your risk. Lifestyle choices could include maintaining a healthy weight, exercising regularly and avoiding beverages containing alcohol.

• #48 Atypical Hyperplasia of the Breast | CommonSpirit Health

  https://www.commonspirit.org/conditions-treatments/atypical-hyperplasia-of-the-breast

  Atypical hyperplasia may be treated by removing the abnormal cells. These may be removed during the breast biopsy. But in some cases, the doctor may make a small cut in the skin to take out more breast tissue. […] Your doctor may have you take medicines to help prevent breast cancer. These may include tamoxifen. If you are past menopause, the medicines may also include aromatase inhibitors. […] Your doctor may have you avoid some medicines. These include birth control pills and hormone replacement therapy. They may increase the risk of breast cancer if you have atypical hyperplasia. […] You will work with your doctor to reduce your risk of breast cancer. You may have a breast exam every 6 months and a mammogram once a year. Your doctor may suggest that you have an MRI scan of the breast. […] Talk to your doctor about ways to reduce your risk of cancer. These may include being active, limiting alcohol, not smoking, eating healthy foods, and staying at a weight that is healthy for you.

• #49 Azthena logo with the word Azthena

  https://www.news-medical.net/health/Atypical-Hyperplasia.aspx

  Women with a diagnosis of atypical hyperplasia have a higher risk of developing breast cancer in future, than those who do not have the condition. For this reason, intensive breast cancer screening and preventive medications to lower the risk of breast cancer is recommended in these cases. […] However, it is worth noting that the majority of women with atypical hyperplasia never develop breast cancer in their lifetime. […] Follow-up breast imaging and examinations must be scheduled as part of screening. […] Follow up with imaging and physical exams are recommended.

• #50 Atypical Hyperplasia – Tower Love Fund – Breast Cancer Explained

  https://www.towercancer.org/resource/breast-cancer-explained/atypical-hyperplasia/

  Atypical ductal hyperplasia (ADH) increases your risk of breast cancer occurring in the breast where the ADH was found. Atypical lobular hyperplasia (ALH) increases your risk of developing breast cancer in both breasts. Keep in mind, though, the vast majority of women diagnosed with ADH or ALH never go on to develop breast cancer. […] The standard treatment for atypical hyperplasia is close follow-up. Monitoring is especially important if you have a strong family history of breast cancer. If you do, you may want to ask your doctor to recommend a program for high-risk women. These programs provide close follow-up, which means clinical breast exams every six months and yearly mammograms. […] If you are diagnosed with atypical hyperplasia, your doctor may suggest that you consider taking tamoxifen. If you are postmenopausal, raloxifene (Evista) may be an option for you as well. Both drugs come in pill form and are taken daily for five years.

Zobacz więcej